Proteinuria and angiotensin converting enzyme (ACE) gene polymorphism

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Proteinuria, traditionally linked to glomerular damage, can directly cause renal damage via tubular fibrosis and inflammatory pathways.
• The renin-angiotensin system, involving angiotensin, is implicated in progressive renal injury, mesangial cell proliferation, and matrix expansion.
• Angiotensin converting enzyme (ACE) gene polymorphisms are investigated for their role in progressive renal failure and response to related therapies.

Purpose of the Study:

• To review the association between angiotensin converting enzyme (ACE) gene polymorphisms and the development of progressive renal failure.
• To examine the role of ACE gene polymorphisms in predicting the response to angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ATRA) therapy for proteinuria.

Main Methods:

• A review of reported studies was conducted, focusing on the deletion/insertion polymorphism of the ACE gene (DD, ID, II genotypes).
• Studies included patients with IgA nephritis and progressive renal failure, analyzing their response to ACEI or ATRA therapy.

Main Results:

• Individuals with the DD genotype of the ACE gene exhibit a higher risk of declining renal function and faster progression to renal failure in IgA nephritis.
• Therapy with ACE inhibitors (ACEI) or angiotensin receptor antagonists (ATRA) demonstrates potential benefits for patients with IgA nephritis, renal impairment, and non-selective proteinuria.
• Treatment may lead to improved protein selectivity, reduced proteinuria, and enhanced renal function.

Conclusions:

• Angiotensin converting enzyme (ACE) genotypes appear to be predictive of the antiproteinuric response to ACE inhibitor (ACEI) therapy.
• ACEI/ATRA therapy likely modifies renal pore size distribution, reducing large, non-selective pores and consequently decreasing urinary protein leakage.